Seno-suppressive molecules as new therapeutic perspectives in rheumatic diseases.
Osteoarthritis
Osteoporosis
Rheumatology
Senescence
Therapies
Journal
Biochemical pharmacology
ISSN: 1873-2968
Titre abrégé: Biochem Pharmacol
Pays: England
ID NLM: 0101032
Informations de publication
Date de publication:
07 2019
07 2019
Historique:
received:
14
01
2019
accepted:
12
03
2019
pubmed:
18
3
2019
medline:
15
2
2020
entrez:
18
3
2019
Statut:
ppublish
Résumé
Over the past years, through in vitro studies and unique animal models, biologists and clinicians have demonstrated that cellular senescence is at the root of numerous age-related chronic diseases including osteoarthritis and osteoporosis. This non-proliferative cellular syndrome can modify other surrounding tissue-resident cells through the establishment of a deleterious catabolic and inflammatory microenvironment. Targeting these deleterious cells through local or systemic seno-therapeutic agent delivery in pre-clinical models improves dramatically clinical signs and extends health span. In this review, we will summarize the current knowledge on cellular senescence, list the different strategies for identifying seno-suppressive therapeutic agents and their translations to rheumatic diseases.
Identifiants
pubmed: 30878551
pii: S0006-2952(19)30103-0
doi: 10.1016/j.bcp.2019.03.017
pii:
doi:
Substances chimiques
Nucleotidyltransferases
EC 2.7.7.-
cGAS protein, human
EC 2.7.7.-
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
126-133Informations de copyright
Copyright © 2019 Elsevier Inc. All rights reserved.